Merck & Co., Inc. (MRK)

73.34
NYSE
Prev Close 73.89
Day Low/High 72.66 / 74.25
52 Wk Low/High 68.38 / 91.40
Exchange NYSE
Shares Outstanding 2525.94B
Market Cap 186.64B
P/E Ratio 17.80
Div & Yield N.A. (N.A)

Latest News

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.

FibroGen Feedback

I continue to get good feedback with regard to FibroGen.   The above is part of a publication on myelodysplastic syndrome.  I would note that Acceleron is being acquired by Merck for $11 billion.  Acceleron has a drug on market which treats 15%-20% ...

Riders on the Storm, More D.C. Nonsense, Early Take on Apple and Amazon

Riders on the Storm, More D.C. Nonsense, Early Take on Apple and Amazon

The two big names disappointed after hours Thursday, but one is more of a concern than the other.

The Worms Turns, O Bank of Canada, Flattening Curve, Ford on Fire, Apple, Amazon

The Worms Turns, O Bank of Canada, Flattening Curve, Ford on Fire, Apple, Amazon

We had almost forgotten that sometimes Mr. Market can still land a ham-sized fist squarely upon that beaming smile of yours.

What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals

What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals

The lack of urgency at the FDA, as it is in the defense space, is alarming.

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

A recent trio of acquisition deals indicates the doldrums in the sector may be over.

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.

Merck Continues to Reward Buyers

Merck Continues to Reward Buyers

Investors are using the available weakness to buy the stock.

The Merck COVID Pill

The reopening trade equities (hotels, airlines, etc.) profited greatly on Friday in large measure because of the Merck  COVID pill announcement.  However, it should be noted that the availability of the pill will be light for months to come.  I have...

Eventually Stocks Will Snap Back

Eventually Stocks Will Snap Back

It is extremely difficult to measure when negative sentiment becomes so extreme that it creates bounce-back conditions, but we are moving in that direction quickly.

Don't Own Merck Stock Yet? Here's My Prescription

Don't Own Merck Stock Yet? Here's My Prescription

I am in this one for the medium to long term.

D.C.'s Not Done Deals, Dissonant Volume, Price Pressures, Real Real Estate Pain

D.C.'s Not Done Deals, Dissonant Volume, Price Pressures, Real Real Estate Pain

Plus, a closer look at a tough Thursday for equities and a rundown on the stocks the author is accumulating.

Serious Thursday, D.C. Dealing, Charting the S&P and Nasdaq, Merck's Antiviral

Serious Thursday, D.C. Dealing, Charting the S&P and Nasdaq, Merck's Antiviral

Is Delta dying down, or is this the calm before the storm up north?

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.

3 Healthcare Stocks for 3%+ Dividend Yields

3 Healthcare Stocks for 3%+ Dividend Yields

These picks are attractive for value-oriented dividend investors looking for strong current income potential.

A Healthy Outlook for Merck and Its Organon Spinoff

A Healthy Outlook for Merck and Its Organon Spinoff

Organon's management team has deep leadership, operating and financial experience.

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

Are traders and investors confused? Possibly. Was that the intent? No, but I think Jerome Powell is fine with that.

Happy Thursday Everyone!

Morning folks, once again we've got a slew of earnings reports and at first blush their coming in a tad better than expected from the likes of Nokia , STMicroelectronics , Wolverine World Wide , Textron , Overstock.com  , and Volkswagen (VLKAY). But...

This Retailer Is Marching Toward Kingship

This Retailer Is Marching Toward Kingship

Walgreens Boots Alliance should benefit from an ageing population and increased demand for medications.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Stand aside for now.

Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings

Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings

Among other things, the president works to align Democratic senators to support his massive Covid relief bill.

Jim Cramer: The Rush to Reopen Is Ill-Advised

Jim Cramer: The Rush to Reopen Is Ill-Advised

Only 7% of Texas is vaccinated, or two million people. I don't want to mess with Texas or Texans until that number is higher.

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.